Biotech hustlers in Boston garages, splicing DNA for the next cancer cure — they’re breathing easier today. PTAB’s fresh nod to Broad Institute’s CRISPR priority means fewer lawsuits dogging their startups, but it’ll cost ‘em in licensing bucks down the line.
The board didn’t budge. On remand from the Federal Circuit, they doubled down: Broad beats UC Berkeley and crew (CVC) to the punch on editing eukaryotic cells with CRISPR-Cas9. That’s the money shot — the version that works in human cells, not just bacteria.
Why Does PTAB Keep Backing Broad?
Look, CVC — that’s UC Regents, Vienna, Charpentier — had their shot. Nobel winners Doudna and Charpentier dreamed big in 2011-12, sketching CRISPR for eukaryotes on paper. But PTAB says nah. No conception without proof it’d click without a lab marathon.
Federal Circuit kicked it back in May, griping PTAB muddled conception (just the idea) with reduction to practice (making it work). Fix that, they said. PTAB did — and still landed on Broad.
“On second review, the PTAB was again ‘not persuaded that CVC has met its burden as junior party of showing that its inventors conceived of an embodiment of Count 1 before the Broad inventors had reduced the invention to practice.’”
That’s the money quote. CVC needed preponderance of evidence. They trotted out notebooks, emails, three arguments. Board shrugged. CVC’s own notes screamed doubt — experiments flopping, tweaks needed. Routine skill? Sure, but not enough to bridge the gap to a working system.
And here’s my take, absent from the filings: this echoes the Myriad Genetics DNA patent saga. Back then, public labs crushed private claims by proving utility first. Broad — MIT, Harvard muscle — played that card perfectly, demoing eukaryotes while CVC sketched. Smart lawyering? Or just better science timing?
Short para punch: Broad wins.
What Changed — Or Didn’t — On Remand?
CAFC zapped PTAB for fixating on CVC scientists’ hand-wringing. “Hey, routine optimization counts toward conception,” they ruled. No need for ironclad success vibes.
PTAB nodded, then pivoted. They weighed it all: witness testimony, those shaky 2012 provisionals (already toast on written description), even post-Broad invention emails from CVC folks still tinkering. Totality? CVC short.
One killer line from the board — a POSA (person of ordinary skill) couldn’t crank out eukaryotic CRISPR from CVC’s “conception” without months of grind. Broad? They reduced to practice January 2013. Game over.
CVC tried derivation too — hey, Broad stole our idea! Email as exhibit. PTAB: prove your conception first, losers.
But zoom out to market ripples. CRISPR’s a $5 billion juggernaut by 2028 forecasts (Statista pegs it higher). Editas Medicine, CRISPR Therapeutics — Broad licensees — stock popped 3% Thursday. CVC allies? Intellia flatlined. Licensing streams? Broad’s now gushing, with deals like Vertex’s $1B+ CRISPR pact intact.
The Real Loser: Innovation Speed?
Here’s the rub — and my bold call. This isn’t victory for science; it’s a toll booth on progress. Broad’s eukaryotic lock-in funnels billions their way (they’ve sued everyone from DuPont to startups). CVC? Pushed to prokaryotes or workarounds.
Data point: since 2012, 20,000+ CRISPR papers, 100+ trials. But patent fog slowed uptake 2-3 years, per McKinsey biotech reports. Real people — patients waiting on sickle cell fixes — pay the delay tax.
Broad’s strategy shines: invent fast, file broad, litigate eternal. CVC gambled on paper tigers; burned millions. Sharp? Yes. Sensible? For academia, maybe. But biotech’s Darwinian — execution trumps genius sketches.
Compare to mRNA vaccines. Moderna-Pfizer raced, patented clinically. No interference quagmires. CRISPR could’ve been that. Instead, decade-long dogfight.
One sentence wonder: Fees rise, therapies crawl.
And don’t sleep on globals. Europe’s EPO sides with CVC sometimes; China’s a wildcard. But U.S. primacy in biotech IP? Broad owns it now.
Why Does This Matter for CRISPR Developers?
Startup founder? Budget 5-10% royalties to Broad. Big Pharma? Negotiation use tanks.
Market dynamics shift hard. Broad’s portfolio — 20+ CRISPR families — covers multiplexing, delivery. CVC’s scraps? Base editing niches.
Prediction: mergers spike. Watch Intellia (CVC-friendly) eye Broad licensees. Or CVC settles quiet, grabs crumbs.
Numbers: Broad’s cashed $500M+ in upfronts since 2017. Post-ruling? Double that in two years.
Wander a sec — remember the Human Genome Project? Celera’s aggressive sequencing lost to public domain ethos. Broad channels that: elite, exclusive.
🧬 Related Insights
- Read more: Paris 2025: AI Safety Summit’s High-Stakes Agenda Unveiled
- Read more: Why TechCrunch Disrupt’s $500 Discount Matters More Than Conference Marketing
Frequently Asked Questions
What is the CRISPR patent dispute about?
It’s a fight over who invented CRISPR-Cas9 for eukaryotic (human-like) cells first: Broad Institute/MIT/Harvard vs. UC Berkeley/Charpentier/Vienna.
Who won the CRISPR patents?
Broad Institute holds priority in the U.S. for eukaryotic applications, per PTAB’s latest ruling.
Will this affect CRISPR therapies coming to market?
Yes — clearer paths but higher licensing costs, potentially delaying affordable treatments by hiking startup expenses.
